title: Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.
abstract: The Functional Activities Questionnaire (FAQ) and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) are frequently used indices of cognitive decline in Alzheimer's disease (AD). The goal of this study was to compare FDG-PET and clinical measurements in a large sample of elderly subjects with memory disturbance. We examined relationships between glucose metabolism in FDG-PET regions of interest (FDG-ROIs), and ADAS-cog and FAQ scores in AD and mild cognitive impairment (MCI) patients enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Low glucose metabolism at baseline predicted subsequent ADAS-cog and FAQ decline. In addition, longitudinal glucose metabolism decline was associated with concurrent ADAS-cog and FAQ decline. Finally, a power analysis revealed that FDG-ROI values have greater statistical power than ADAS-cog to detect attenuation of cognitive decline in AD and MCI patients. Glucose metabolism is a sensitive measure of change in cognition and functional ability in AD and MCI, and has value in predicting future cognitive decline.
authors: Helen Wills Neuroscience Institute, University of California-Berkeley, CA 94720-3190, USA. slandau@berkeley.edu
authors: Susan M
authors: SM
authors: Landau
authors: Danielle
authors: D
authors: Harvey
authors: Cindee M
authors: CM
authors: Madison
authors: Robert A
authors: RA
authors: Koeppe
authors: Eric M
authors: EM
authors: Reiman
authors: Norman L
authors: NL
authors: Foster
authors: Michael W
authors: MW
authors: Weiner
authors: William J
authors: WJ
authors: Jagust
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000503:physiopathology* / Q000523:psychology*; D001786:Blood Glucose / Q000378:metabolism; D060825:Cognitive Dysfunction / Q000000981:diagnostic imaging / Q000503:physiopathology* / Q000523:psychology*; D004185:Disability Evaluation; D018450:Disease Progression; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests / Q000592:standards; D049268:Positron-Emission Tomography / Q000379:methods* / Q000592:standards; D011237:Predictive Value of Tests; D012720:Severity of Illness Index
chemical_list: D001786:Blood Glucose; D019788:Fluorodeoxyglucose F18